Nasdaq

Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin

JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a ...
Action Reporter Media

Fermbox and Dyadic Launch 1st Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Our animal-origin free recombinant proteins and enzymes portfolio, developed with Dyadic, augments Fermbox’s strategy of developing products that balance commercial scale with strong margin potential.

BETMAT Releases Comprehensive Industry Guide on Endotoxin Compliance for Injectable Pharmaceuticals

To address these critical safety requirements, BETMAT Biotechnology LLC has released a specialized operational guide focused on Reliable Endotoxin Testing For Injectable Pharmaceuticals, a systematic ...
Business Insider

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company ...